标题
Mutant-selective degradation by BRAF-targeting PROTACs
作者
关键词
-
出版物
Nature Communications
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-11
DOI
10.1038/s41467-021-21159-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of Selective Small Molecule Degraders of BRAF-V600E
- (2020) Xiao-Ran Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Functional characterization of a PROTAC directed against BRAF mutant V600E
- (2020) Ganna Posternak et al. Nature Chemical Biology
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
- (2019) Ruth Röck et al. Science Advances
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
- (2018) Matthew Dankner et al. ONCOGENE
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- Structural Basis for the Non-catalytic Functions of Protein Kinases
- (2016) Jennifer E. Kung et al. STRUCTURE
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
- (2015) Tu Nguyen-Ngoc et al. Journal of Thoracic Oncology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
- (2014) Jacob R. Haling et al. CANCER CELL
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
- (2014) L. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface
- (2012) Inge Van Molle et al. CHEMISTRY & BIOLOGY
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
- (2012) B. Sen et al. Science Translational Medicine
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Targeting mutant BRAF in metastatic melanoma
- (2010) Alexandra Flemming NATURE REVIEWS DRUG DISCOVERY
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started